Plain-English translation of NCT04585958 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether (a targeted cancer drug) works better when combined with (a different type of cancer medication) in patients with advanced cancers that have a specific protein called HER2. Researchers want to find the safest dose of these two medications together and see how well this combination helps patients, especially those with ovarian cancer that has stopped responding to standard chemotherapy.
Some cancers stop responding to standard treatments, leaving patients with limited options. This study explores whether combining two different types of cancer-fighting medications might work better than using them separately, and whether this approach could help patients whose cancer has become resistant to previous treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive as an intravenous infusion (into your vein) once every three weeks, and take pills by mouth twice daily on a rotating schedule during each treatment cycle. You will attend regular clinic visits for blood tests, heart imaging (ECHO or MUGA scan), CT scans, and possibly tumor biopsies to monitor how you're responding and check for side effects. This is an ongoing treatment study with cycles repeating every 21 days as long as your cancer isn't progressing and you're tolerating the medications well.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States